Cargando…

Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer

Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Karabulut, Mehmet, Afsar, Cigdem Usul, Alıs, Halil, Oran, Ebru, Karabulut, Senem, Akarsu, Cevher, Sahbaz, Nuri Alper, Gümüsoglu, Alpen Yahya, Bilgin, Elif, Aykan, Nuri Faruk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666662/
https://www.ncbi.nlm.nih.gov/pubmed/29142750
http://dx.doi.org/10.3892/mco.2017.1405
_version_ 1783275347648708608
author Karabulut, Mehmet
Afsar, Cigdem Usul
Alıs, Halil
Oran, Ebru
Karabulut, Senem
Akarsu, Cevher
Sahbaz, Nuri Alper
Gümüsoglu, Alpen Yahya
Bilgin, Elif
Aykan, Nuri Faruk
author_facet Karabulut, Mehmet
Afsar, Cigdem Usul
Alıs, Halil
Oran, Ebru
Karabulut, Senem
Akarsu, Cevher
Sahbaz, Nuri Alper
Gümüsoglu, Alpen Yahya
Bilgin, Elif
Aykan, Nuri Faruk
author_sort Karabulut, Mehmet
collection PubMed
description Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA. A total of 40 age- and sex-matched healthy controls were included in the analysis. The median age of patients was 60 years (range, 24–84 years); the majority of the tumor localization was to the colon (n=81, 58%). The median follow-up time was 14 months, while 43 (31%) patients experienced disease progression and 31 (22%) succumbed to the disease. A total of 81 patients (58%) were in the early stages of disease (stage II and III), and 42% of the patients had stage IV disease. The estimated 2-year overall and 1-year progression-free survival rates for the whole patient group were 70% [95% confidence interval (CI): 58.8–81.2] and 26.2% (95% CI: 12.9–39.5), respectively. The number of patients who received neoadjuvant treatment was 37. Of the patients who were administered palliative treatment, 24 received oxaliplatin, whereas 22 received irinotecan and 9 received fluorouracil/capecitabine. A total of 36 and 15 of the patients who received targeted therapy were administered bevacizumab and cetuximab, respectively. Of the 55 patients with metastatic disease who received palliative chemotherapy (CTx), 31% were CTx-responsive. The baseline median sEGFR levels were significantly higher in patients with CRC compared with the healthy control group (P=0.002). In addition, established clinical variables, including no surgical resection, metastatic stage, higher pathological tumor stage, poorer regression score (3–4) and higher lactate dehydrogenase levels, were found to be associated with higher sEGFR levels (P=0.03, P=0.009, P=0.05, P=0.05 and P=0.05, respectively). The results of the present study did not reveal statistically significant associations between sEGFR concentrations and overall and progression-free survival rates. In conclusion, sEGFR concentrations may be diagnostic markers in patients with CRC; however, their predictive and prognostic values were not determined.
format Online
Article
Text
id pubmed-5666662
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56666622017-11-15 Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer Karabulut, Mehmet Afsar, Cigdem Usul Alıs, Halil Oran, Ebru Karabulut, Senem Akarsu, Cevher Sahbaz, Nuri Alper Gümüsoglu, Alpen Yahya Bilgin, Elif Aykan, Nuri Faruk Mol Clin Oncol Articles Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA. A total of 40 age- and sex-matched healthy controls were included in the analysis. The median age of patients was 60 years (range, 24–84 years); the majority of the tumor localization was to the colon (n=81, 58%). The median follow-up time was 14 months, while 43 (31%) patients experienced disease progression and 31 (22%) succumbed to the disease. A total of 81 patients (58%) were in the early stages of disease (stage II and III), and 42% of the patients had stage IV disease. The estimated 2-year overall and 1-year progression-free survival rates for the whole patient group were 70% [95% confidence interval (CI): 58.8–81.2] and 26.2% (95% CI: 12.9–39.5), respectively. The number of patients who received neoadjuvant treatment was 37. Of the patients who were administered palliative treatment, 24 received oxaliplatin, whereas 22 received irinotecan and 9 received fluorouracil/capecitabine. A total of 36 and 15 of the patients who received targeted therapy were administered bevacizumab and cetuximab, respectively. Of the 55 patients with metastatic disease who received palliative chemotherapy (CTx), 31% were CTx-responsive. The baseline median sEGFR levels were significantly higher in patients with CRC compared with the healthy control group (P=0.002). In addition, established clinical variables, including no surgical resection, metastatic stage, higher pathological tumor stage, poorer regression score (3–4) and higher lactate dehydrogenase levels, were found to be associated with higher sEGFR levels (P=0.03, P=0.009, P=0.05, P=0.05 and P=0.05, respectively). The results of the present study did not reveal statistically significant associations between sEGFR concentrations and overall and progression-free survival rates. In conclusion, sEGFR concentrations may be diagnostic markers in patients with CRC; however, their predictive and prognostic values were not determined. D.A. Spandidos 2017-11 2017-09-01 /pmc/articles/PMC5666662/ /pubmed/29142750 http://dx.doi.org/10.3892/mco.2017.1405 Text en Copyright: © Karabulut et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Karabulut, Mehmet
Afsar, Cigdem Usul
Alıs, Halil
Oran, Ebru
Karabulut, Senem
Akarsu, Cevher
Sahbaz, Nuri Alper
Gümüsoglu, Alpen Yahya
Bilgin, Elif
Aykan, Nuri Faruk
Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title_full Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title_fullStr Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title_full_unstemmed Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title_short Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
title_sort evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666662/
https://www.ncbi.nlm.nih.gov/pubmed/29142750
http://dx.doi.org/10.3892/mco.2017.1405
work_keys_str_mv AT karabulutmehmet evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT afsarcigdemusul evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT alıshalil evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT oranebru evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT karabulutsenem evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT akarsucevher evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT sahbaznurialper evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT gumusoglualpenyahya evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT bilginelif evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer
AT aykannurifaruk evaluationofepidermalgrowthfactorreceptorserumlevelsandtheirassociationwithclinicopathologicalcharacteristicsinpatientswithcolorectalcancer